Outlook Therapeutics Stock (NASDAQ: OTLK)

Outlook Therapeutics (NASDAQ:OTLK) Stock

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Deutsche Bank analyst David Begleiter maintains Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) with a Buy and raises the price target from $14 to $22.

News

Price Target

Analyst Ratings

Deutsche Bank Maintains Buy on Compass Minerals Intl, Raises Price Target to $22

<ul>
<li>The offering is being led by several preeminent global investment firms</li>
<li>Company total cash position expected to exceed $350 million following closing</li>
</ul>
HOBOKEN, N.J., June 23, 2025 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>), an innovative, integrated photonics and quantum optics technology company, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 14,035,089 shares of common stock in a private placement at a purchase price of $14.25 per share. The offering is expected to result in gross proceeds of $200 million, before deducting offering expenses. The closing of the offering is expected to occur on or about June 24, 2025, subject to the satisfaction of customary closing conditions.

QUBT

Quantum Computing Announces Private Placement of 14M Shares at $14.25/Shr

GLJ Research analyst Austin Wang initiates coverage on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Buy rating and announces Price Target of $702.

Initiation

GLJ Research Initiates Coverage On GE Vernova with Buy Rating, Announces Price Target of $702

Digital Ally, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) today announced it has signed a Master Distribution Agreement (the "Agreement") with Redwood Scientific Technologies ("Redwood"), granting Digital Ally exclusive global rights to distribute Redwood's clinically-driven nicotine cessation products, including TBX-Free and TBX Vape-Free.
This Agreement establishes Digital Ally as the exclusive commercialization partner for a first-of-its-kind product designed to help Americans overcome addiction to vape devices. TBX Vape-Free, delivered via oral thin-film technology, is expected to be the first product of its kind to directly target vape-related nicotine dependency. This Agreement provides Digital Ally the exclusive global rights to Redwood's full range of technologies, brands, trademarks, manufacturing processes, vendor relationships, and additional essential assets.

DGLY

Digital Ally Sign Master Distribution Agreement With Redwood Scientific, Granting Digital Ally Exclusive Global Rights To Distribute Redwood's Clinically-Driven Nicotine Cessation Products, Including TBX-Free And TBX Vape-Free

Deutsche Bank analyst Paul Trussell maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Hold and raises the price target from $57 to $67.

Deutsche Bank Maintains Hold on Kroger, Raises Price Target to $67

Patient Treated with OneRF&#xAE; Ablation System Previously Experienced up to 10 Seizures a Day
EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara—an early patient treated with the Company's patented OneRF&#xAE; Ablation System—has successfully surpassed the one year milestone of being seizure free.
Clara was one of the first patients to undergo treatment using NeuroOne's OneRF&#xAE; platform. Since the procedure in June 2024, Clara has been completely seizure-free, which has greatly improved her quality of life.

NMTC

NeuroOne Medical Technologies Patient Treated With Patented OneRF Ablation System Surpasses One Year Milestone Of Being Seizure Free

Scotiabank analyst Andres Coello downgrades AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) from Sector Outperform to Sector Perform and announces $45.4 price target.

Downgrades

ASTS

Scotiabank Downgrades AST SpaceMobile to Sector Perform, Announces $45.4 Price Target

Deutsche Bank analyst Steve Powers upgrades Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) from Hold to Buy and raises the price target from $71 to $95.

Upgrades

Deutsche Bank Upgrades Estee Lauder Cos to Buy, Raises Price Target to $95

As of June 23, 2025, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">MAG Silver Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAG#NYSE">MAG</a>)</h3>
<ul class="wp-block-list">
<li>On June 10, MAG Silver filed management circular ahead of July 10 vote on $2.1 billion Pan American acquisition deal. The company's stock jumped around 13% over the past month and has a 52-week high of $21.83.</li>
<li>RSI Value: 74.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>MAG Price Action: Shares of MAG Silver fell 1.1% to close at $21.18 on Friday.</li>
<li>Edge Stock Ratings: 93.91 Momentum score.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/MAG"><img loading="lazy" decoding="async" width="440" height="180" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23041051/image-326.png" alt="" class="wp-image-957693" style="width:298px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23041051/image-326.png 440w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23041051/image-326-300x123.png 300w" sizes="(max-width: 440px) 100vw, 440px" /></a></figure>
<h3 class="wp-block-heading">TMC the metals company Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, TMC announced an $85.2 million strategic investment from Korea Zinc for 19.6 million shares at $4.34 each, including 3-year warrants for 6.9 million shares at $7.00 and rights to maintain equity stake. &#8220;We&#8217;re thrilled to welcome Korea Zinc as a strategic investor and partner on our journey to redefine how the United States sources critical minerals for energy, defense, manufacturing and infrastructure,&#8221; said Gerard Barron, Chairman and CEO of The Metals Company. The company's stock gained around 42% over the past five days and<a href="https://www.benzinga.com/quote/TMC"> has a 52-week high </a>of $7.40.</li>
<li>RSI Value: 72.8</li>
<li>TMC Price Action: Shares of TMC the metals company fell 2.8% to close at $6.56 on Friday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

Top 2 Materials Stocks That May Collapse In Q2

AREC

American Resources, ReElement, And Pensana Sign MOU To Advance Global Rare Earth Strategy

Citigroup analyst Leandro Bastos initiates coverage on Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) with a Buy rating and announces Price Target of $10.

VTEX

Citigroup Initiates Coverage On Vtex with Buy Rating, Announces Price Target of $10

GAIA

Gaia Expects To Join Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

Citigroup analyst Vikram Bagri initiates coverage on NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) with a Neutral rating and announces Price Target of $46.

Citigroup Initiates Coverage On NuScale Power with Neutral Rating, Announces Price Target of $46

WIIM

SMCI

Super Micro Computer shares are trading lower after the company announced a proposed $2 billion convertible senior notes offering.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgalatea.bio%2F&amp;esheet=54280367&amp;newsitemid=20250623728878&amp;lan=en-US&amp;anchor=Galatea+Bio&amp;index=1&amp;md5=615f1b994c4138ccae89597ad0ea54cd">Galatea Bio</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffabricgenomics.com%2F&amp;esheet=54280367&amp;newsitemid=20250623728878&amp;lan=en-US&amp;anchor=Fabric+Genomics&amp;index=2&amp;md5=8f69dadc2e94ff96640da98a5911d803">Fabric Genomics</a>, a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genedx.com%2F&amp;esheet=54280367&amp;newsitemid=20250623728878&amp;lan=en-US&amp;anchor=GeneDx&amp;index=3&amp;md5=d9913e73e78f5f5279ae1bf121b3fc0c">GeneDx</a> company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.
The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers.

Galatea Bio And GeneDx's Fabric Genomics Collaborate To Enhance Genetic Testing By Incorporating Both Rare Pathogenic Variant Analysis And PRS To Assess Genetic Susceptibility To Common Diseases

SIDU

Sidus Space Selects Atomic-6  As Its Solar Array Partner For The Cislunar Data Satellite Mission

ORRF

Orrstown Financial Services Board Authorizes To Repurchase Up To 500,000 Shares, Representing ~2.5% Of Outstanding Common Stock

Craig-Hallum analyst Ryan Sigdahl initiates coverage on Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) with a Buy rating and announces Price Target of $75.

SPHR

Craig-Hallum Initiates Coverage On Sphere Entertainment with Buy Rating, Announces Price Target of $75

ECDA

ECD Automotive Design shares are trading higher after the company signed a $500 million equity facility to pursue a bitcoin treasury strategy.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

Outlook Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL